Many factors to consider
“For example, we know very little about the predictive factors for response. It is important that, as clinical academics, we encourage the industry to study what is happening in the tumors within the immune environment. How is it changing with these drugs, especially with chemotherapy? What is changing when you add bevacizumab? We must understand what it is that make some patients benefit quite well and others not at all. This could be simple things, such as measuring PD-1 and PD-L1. Is it an oversimplification? It certainly could be in the field of ovarian cancer, but possibly other cancers, as well,” said professor Ledermann.